HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.

AuthorsGiuseppe Visani, Pietro Maria Stefani, Saveria Capria, Lara Malerba, Piero Galieni, Francesco Gaudio, Giorgina Specchia, Giovanna Meloni, Filippo Gherlinzoni, Roberta Gonella, Marco Gobbi, Armando Santoro, Felicetto Ferrara, Marco Rocchi, Enrique M Ocio, Maria Dolores Caballero, Federica Loscocco, Alessandro Isidori
JournalBlood (Blood) Vol. 124 Issue 19 Pg. 3029-31 (Nov 06 2014) ISSN: 1528-0020 [Electronic] United States
PMID25377565 (Publication Type: Clinical Trial, Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents, Alkylating
  • Nitrogen Mustard Compounds
  • Cytarabine
  • Bendamustine Hydrochloride
  • Melphalan
Topics
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Antineoplastic Agents, Alkylating (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Bendamustine Hydrochloride
  • Combined Modality Therapy
  • Cytarabine (therapeutic use)
  • Drug Resistance, Neoplasm
  • Hematopoietic Stem Cell Transplantation (methods)
  • Humans
  • Lymphoma, Non-Hodgkin (drug therapy)
  • Melphalan (therapeutic use)
  • Nitrogen Mustard Compounds (therapeutic use)
  • Transplantation, Autologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: